BioRestorative Therapies (BRTX) Prepaid Assets (2011 - 2025)
BioRestorative Therapies' (BRTX) quarterly Prepaid Assets came in at $168440.0 in Q4 2025, down 24.54% YoY from $223230.0 in Q4 2024, and down 17.53% on a QoQ basis from $204237.0 in Q3 2025.
BioRestorative Therapies (BRTX) Prepaid Assets (2011 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 15 years of Prepaid Assets data on file, last reported at $168440.0 in Q4 2025.
- Quarterly Prepaid Assets fell 24.54% year-over-year to $168440.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $168440.0 (down 24.54% YoY) and the FY2025 annual result came in at $168440.0, down 24.54% from the prior year.
- Prepaid Assets fell to $168440.0 in Q4 2025, from $204237.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $540280.0 in Q1 2022 to a low of $31956.0 in Q3 2021.
- A 5-year average of $276086.4 and a median of $300546.0 in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets surged 1014.18% — and 2025, when it tumbled 31.77%.
- Tracing BRTX's Prepaid Assets over 5 years: stood at $436181.0 in 2021, then declined by 16.76% to $363082.0 in 2022, then slipped by 15.93% to $305231.0 in 2023, then retreated by 26.87% to $223230.0 in 2024, then decreased by 24.54% to $168440.0 in 2025.
- The last three Prepaid Assets figures came in at $168440.0 (Q4 2025), $204237.0 (Q3 2025), and $201871.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 168,440.00 |
| Sep 30, 2025 | 204,237.00 |
| Jun 30, 2025 | 201,871.00 |
| Mar 31, 2025 | 217,400.00 |
| Dec 31, 2024 | 223,230.00 |
| Sep 30, 2024 | 233,697.00 |
| Jun 30, 2024 | 295,861.00 |
| Mar 31, 2024 | 316,963.00 |
| Dec 31, 2023 | 305,231.00 |
| Sep 30, 2023 | 325,931.00 |
| Jun 30, 2023 | 403,559.00 |
| Mar 31, 2023 | 393,054.00 |
| Dec 31, 2022 | 363,082.00 |
| Sep 30, 2022 | 356,046.00 |
| Jun 30, 2022 | 374,493.00 |
| Mar 31, 2022 | 540,280.00 |
| Dec 31, 2021 | 436,181.00 |
| Sep 30, 2021 | 31,956.00 |
| Jun 30, 2021 | 54,764.00 |
| Mar 31, 2021 | 75,452.00 |